Utilizing ICIs to block inhibitory PD-1/PD-L1 and CTLA-4/CD80/86 signaling pathways improves the generation of efficient immune responses against cancer cells, revitalizes tumor antigen recognition, and ultimately leads to tumor death [10]. The gene discussed is RPL17; the disease is cancer.